| abstract |
REFERS TO CYCLOPROPYLAMINE DERIVATIVES OF FORMULA (I), WHERE ONE OF R1 AND R2 IS -L2-R6a-L3-R6b, OR THE OTHER R1 AND R2 IS H, ALKYL, ALCOXY, HALOGEN, AMONG OTHERS; R6a IS HETEROARYL OF 5 OR 6 MEMBERS, CYANOPHENYL, BICYCLIC HETEROARYL OF 8 TO 12 MEMBERS, AMONG OTHERS; R6b IS H, HETEROARYL OF 5 0 6 MEMBERS, ARYL, AMONG OTHERS; L IS - [C (R16) (R17)] k, WHERE R16 AND R17 ARE EACH H AND ALKYL; k IS 1, 2 O 3; L2 IS ALKYLENE, -O-, -C (= O) -, AMONG OTHERS; L3 IS ALKYLENE, -C (= O) -, -S-, AMONG OTHERS; R3, R3a AND R3b ARE EACH H, ALKYL, TRIFLUOROALKYL, AMONG OTHERS; R4 AND R5 ARE EACH ALKYL, FLUOROALKYL, HYDROXYALKYL, AMONG THE OTHERS. PREFERRED COMPOUNDS ARE: 2´ - ((1S, 2S) -2 - {[(2S) -2-METHYLPYRROLIDIN-1-IL] METHYL} CYCLOPROPYL) -1,1´-BIPHENYL-4-CARBONITRILE, 1- [4 - ((1S-2S) -2 - {[(2S) -2-METHYLPYRROLIDIN-1-IL] METHYL} CYCLOPROPYL) PHENYL] AZEPAN-2-ONA, (S) -3-HYDROXY-1- (4- ( (1S, 2S) -2-METHYLPYRROLIDIN-1-IL) METHYL) CYCLOPROPYL) PHENYL) PYRROLIDIN-2-ONA, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION METHOD FOR A PHARMACEUTICAL COMPOSITION THAT CONTAINS IT. SAID COMPOUND MODULATES THE ACTIVITY OF THE HISTAMINE-3 RECEPTOR, BEING USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD), AMONG OTHERS |